News & Updates

MRI-derived biomarkers pinpoint NASH patients at high risk of progression

The quantitative magnetic resonance imaging (MRI)-derived biomarkers cT1 and liver fat demonstrate good performance for identifying patients with nonalcoholic steatohepatitis (NASH) who have the highest risk of disease progression, as reported in a study.

Abnormal myocardial blood flow reserve predicts death in heart transplant recipients

Heart transplant recipients appear to be at an increased risk of mortality or retransplantation if they have abnormal myocardial blood flow reserve (MBFR), even in the absence of epicardial cardiac allograft vasculopathy (CAV), according to a study.

High protein, calcium diet plus exercise protects bone health in pregnancy

A high protein and calcium diet in pregnant women, together with normal vitamin D status, lessens bone resorption and preserves bone formation, potentially resulting in bone health protection during pregnancy, suggests a study.

Hot flashes in menopause linked to gut barrier permeability

Levels of the fatty acid binding protein 2 (FABP2) appear to be correlated with hot flushes in post-menopausal women, suggesting a role of intestinal barrier permeability in symptomatology, a recent study has found.

Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.

Ivermectin of no benefit in mild-to-moderate COVID-19

The use of ivermectin in the treatment of outpatients with mild-to-moderate COVID-19 falls short of improving time to recovery when compared with placebo, a study has shown.